Ginger Chu

@Kidney_Trials @YJCho16 @ANZSN 100%!!!

⁦@YJCho16⁩ highlighting the importance of investigator initiated clinical trials ⁦@ANZSN⁩

Calling @ANZSN members Only: please complete this survey on #Pacific region engagement- even if you are not involved with the Pacific region, there are still important questions for you! Please help us shape the future of Pacific #Nephrology! research.net/r/LMDNNDV

Get your A/L request in early and join us in Christchurch New Zealand RenalSociety of Australasia Conference June 18-20 2026. 🙌🙌🙌

Our latest systematic review and network meta-analysis provides optimal interventions for managing AVF cannulation-related pain in patients receiving hemodialysis. @Profritin @emanias1 @Gingerchu3 @DrPMDavidson doi.org/10.1016/j.ijnu…

Coming back to X to promote the incredible work of the @ISNeducation Train the Trainer group and this toolkit ! A ready made set of slides with notes on #pregnancy and #kidney topics. Just download, read, then teach ! Spread the word on #obstetricnephrology

Topical Timolol in the Treatment of #Hemodialysis Tunneled Catheter Exit-Site Pyogenic #Granuloma #KIRNephrologyRounds

The Important Role of Sleep in CKD Prevention and Progression - Kidney International Reports kireports.org/article/S2468-…

1️⃣ minute 2️⃣ questions 2️⃣7️⃣ languages Check to see if you are at risk for kidney disease by taking the #ISNquiz quiz now: lite.spr.ly/6000GPqA #KidneyHealthMatters #KidneyHealthForAll

I am pleased to share our phd student’s work. Dr Majid Alotni who successfully published 3 articles as part of his phd work! linkedin.com/posts/ginger-c…

Effectiveness of mental health chatbots in depression and anxiety for adolescents and young adults: a meta-analysis of randomized controlled trials: Expert Review of Medical Devices: Vol 0, No 0 - Get Access tandfonline.com/doi/full/10.10…

Want to know what is the current evidence in sleep disturbance in people with chronic kidney disease? Check out the recent umbrella review published by our team👇 url.au.m.mimecastprotect.com/s/KJmVCgZ0y3cA… @shilpa_jes @RenalRusso @FernandezRitin @a_viecelli @Pauldialysis

@KrishnanAmrish @shilpa_jes Congratulations Shilpa! So well deserved!!! 👍👍👍

Incredibly well deserved for your relentless dedication & commitment to education in Nephrology in Australia 🇦🇺, Fiji 🇫🇯, for being a mentor to many young nephrologists, physicians, and med students from our region. Massive congratulations Dr Shilpa Jesudason ⁦@shilpa_jes⁩

A milestone day ! My third “baby” Is born ! With @ISNeducation @ISNkidneycare we launched the #Pregnancy and #Kidneydisease tool kit - the culmination of nearly 2 years of work from our #ISN Train the Trainer Faculty and Trainers See the QR code for links to the tool kit

REGISTER: thelimbic.com/nephrology/key… Join an expert discussion on the latest advances in IgA nephropathy (IgAN), focusing on the recent KDIGO guidelines, understanding the pathophysiology of the disease & the evolving treatment landscape. @muhgeot @ANZSN

Umbrella Reviews: A methodological guide academic.oup.com/eurjcn/article…

We are pleased to announce the publication of the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Read the news release: kdigo.co/2025-ADPKD-Gui… This first-ever KDIGO guideline focused on a rare kidney disease provides practical tools for healthcare providers and patients to improve diagnosis, care, and treatment, addressing challenges in managing this inherited condition. "This comprehensive guideline reflects the significant progress in ADPKD research over the last decade, from genetic insights to advanced therapies," said Guideline Co-Chair Vicente E. Torres, MD. "By addressing the complexities of diagnosis, treatment, and management, we hope this guideline will standardize care, enhance clinical practices, and help reduce the global burden of ADPKD. Our goal is that this resource will not only empower clinical decision-making but also inspire hope for patients and their families, demonstrating that meaningful progress is achievable for this challenging disease." "The publication of this guideline represents a pivotal step forward in the care of ADPKD and people with rare genetic disorders worldwide," said Guideline Co-Chair Olivier Devuyst, MD. "It is the result of an extraordinary global collaboration among experts, researchers, and patient advocates, bringing together the best available evidence to guide care across diverse settings. This guideline is not just important for individuals with ADPKD. It also serves as a crucial template for the development of guidance for other rare genetic conditions. By providing a roadmap for consistent, evidence-based care, it addresses critical knowledge and practice gaps worldwide, offering a model for improving the lives of those with rare diseases globally." Download the KDIGO ADPKD Guideline, Executive Summary, and Data Supplement on the guideline website: kdigo.co/ADPKD Read the guideline in @Kidney_Int: kdigo.co/ADPKD-Guidelin… #ADPKD

In-Centre #Haemodialysis and Patient #Travel #Time in Aotearoa New Zealand: a Nationwide Geospatial and Data Linkage Study #VisualAbstract by @elbaonelida kireports.org/article/S2468-… @CODE_USyd @johanna_birrell @angelacwebster @Nickii_dlm